Attached files

file filename
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR33.htm
EX-32 - EXHIBIT 32.1 - IRIS BIOTECHNOLOGIES INCirsb11132012exh321.htm
EXCEL - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR2.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR7.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR3.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR4.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR8.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR5.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR1.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR9.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR32.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR25.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR23.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR27.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR10.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR19.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR34.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR16.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR14.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR18.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR28.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR17.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR11.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR12.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR15.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR26.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR29.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR24.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR30.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR31.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR22.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR13.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR21.htm
10-Q - FORM 10-Q - IRIS BIOTECHNOLOGIES INCirsb11082012form10q.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR6.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR20.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Simon Chin, certify that:

 

1.    I have reviewed this quarterly report on Form 10-Q of Iris Biotechnologies Inc.;

 

2.    Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.    Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

  b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

 

  d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

 5.    I have disclosed, based on my most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

  a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

 

  a) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

 

 Date: November 13, 2012 By: /s/ Simon Chin
   

Simon Chin

President, Chief Executive Officer and Chief Financial Officer